Incretin Atlas › Molecules › Berobenatide (MET-097i)
Berobenatide (MET-097i)
GLP-1 (ultra-long-acting, monthly) · s.c. monthly · Pfizer (Metsera)
Summary
- Also known as
- Metsera (Pfizer)
- Mechanism
- GLP-1 (ultra-long-acting, monthly)
- Route
- s.c. monthly
- Company
- Pfizer (Metsera)
- Highest development stage
- phase 3
- Status (as of data cut)
- Phase 3 started 2026 (monthly dosing); phase 2b VESPER reported 2025 verify
- Next milestone
- Phase 3; combination with amylin MET-233i
Sources for the status
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 2 phase 3 ongoing | Phase 3 ongoing (monthly dosing) | Phase 3 |
| T2D | 0 no data | ||
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 2 phase 3 ongoing | Phase 3 ongoing | |
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
No trial arms with extracted efficacy or tolerability data yet.
Registered trials (13)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| VESPER-SUI The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight | Obesity | Phase 3 | not yet recruiting | 2026-11 → 2028-10 | 900 | not yet recruiting | NCT07932925 |
| VESPER-JW A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW) | Obesity | Phase 3 | recruiting | 2026-10 → 2029-03 | 180 | recruiting | NCT07794761 |
| NCT07874633 · China A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity | Obesity | Phase 3 | recruiting | 2026-10 → 2028-06 | 432 | recruiting | NCT07874633 |
| VESPER-OSA 2 A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2) | Sleep apnoea | Phase 3 | recruiting | 2026-10 → 2028-06 | 258 | recruiting | NCT07881757 |
| VESPER-OA 2 A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2) | Knee OA | Phase 3 | recruiting | 2026-10 → 2028-08 | 756 | recruiting | NCT07915609 |
| VESPER-OA 1 A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1) | Knee OA | Phase 3 | recruiting | 2026-10 → 2028-08 | 656 | recruiting | NCT07919678 |
| NCT07792954 · China A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity | Obesity | Phase 3 | recruiting | 2026-09 → 2028-03 | 300 | recruiting | NCT07792954 |
| VESPER-JM A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM) | Obesity | Phase 3 | recruiting | 2026-09 → 2029-02 | 197 | recruiting | NCT07794774 |
| VESPER-OSA 1 A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1) | Sleep apnoea | Phase 3 | recruiting | 2026-09 → 2028-04 | 258 | recruiting | NCT07823608 |
| VESPER-SWITCH A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity | Obesity | Phase 3 | recruiting | 2026-09 → 2028-02 | 660 | recruiting | NCT07845500 |
| VESPER-6 A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity | Obesity | Phase 3 | recruiting | 2026-06 → 2028-05 | 954 | recruiting | NCT07595549 |
| NCT07400653 A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | Obesity | Phase 3 | active not recruiting | 2026-02 → 2027-10 | 1078 | active not recruiting | NCT07400653 |
| VESPER-4 Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity | Obesity | Phase 3 | active not recruiting | 2025-12 → 2027-09 | 3578 | active not recruiting | NCT07311850 |
Primary sources
No source recorded.
How to cite this page
Medical Adviser's Group. Incretin Atlas: Berobenatide (MET-097i). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/berobenatide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.